Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Sally Temraz, Fadi Nasr, Joseph Kattan, Dany Abigerges, Walid Moukadem, Fadi Farhat, Layal Maatouk, Georges Chahine & Ali Shamseddine. (2022) A Non-Interventional Multicenter Study of First-Line Bevacizumab in Combination with Chemotherapy in Patients with Metastatic Colorectal Cancer in Lebanon. Biologics: Targets and Therapy 16, pages 7-15.
Read now
Read now
Emerik Osterlund & Bengt Glimelius. (2022) Temporal development in survival, and gender and regional differences in the Swedish population of patients with synchronous and metachronous metastatic colorectal cancer. Acta Oncologica 61:10, pages 1278-1288.
Read now
Read now
Bengt Glimelius & Per Pfeiffer. (2018) Do we make progress in elderly patients with metastatic colorectal cancer?. Acta Oncologica 57:11, pages 1422-1426.
Read now
Read now
Eetu Heervä, Anu Carpelan, Samu Kurki, Jari Sundström, Heikki Huhtinen, Arto Rantala, Annika Ålgars, Raija Ristamäki, Olli Carpén & Heikki Minn. (2018) Trends in presentation, treatment and survival of 1777 patients with colorectal cancer over a decade: a Biobank study. Acta Oncologica 57:6, pages 735-742.
Read now
Read now
Alberto Russi, Vera Damuzzo, Marco Chiumente, Jacopo Pigozzo, Marco Cesca, Vanna Chiarion-Sileni & Angelo Claudio Palozzo. (2017) Ipilimumab in real-world clinical practice: efficacy and safety data from a multicenter observational study. Journal of Chemotherapy 29:4, pages 245-251.
Read now
Read now
Articles from other publishers (7)
Nuttavut Sumransub, Kornpong Vantanasiri, Ajay Prakash & Emil Lou. (2021) Advances and new frontiers for immunotherapy in colorectal cancer: Setting the stage for neoadjuvant success?. Molecular Therapy - Oncolytics 22, pages 1-12.
Crossref
Crossref
Sara Lonardi, Guglielmo Nasti, Daniele Fagnani, Donatello Gemma, Libero Ciuffreda, Cristina Granetto, Sara Lucchesi, Alberto Ballestrero, Maria Biglietto, Ilaria Proserpio, Francesca Bergamo, Emanuela Proietti & Giuseppe Tonini. (2019) Discontinuation of first-line bevacizumab in metastatic colorectal cancer: the BEAWARE Italian Observational Study. Tumori Journal 105:3, pages 243-252.
Crossref
Crossref
Matteo Franchi, Sandro Barni, Giovanna Tagliabue, Paolo Ricci, Walter Mazzucco, Rosario Tumino, Antonietta Caputo & Giovanni Corrao. (2019) Effectiveness of First-Line Bevacizumab in Metastatic Colorectal Cancer: The Observational Cohort Study GRETA. The Oncologist 24:3, pages 358-365.
Crossref
Crossref
Stine Braendegaard Winther, Pia Österlund, Åke Berglund, Bengt Glimelius, Camilla Qvortrup, Halfdan Sorbye & Per Pfeiffer. (2017) Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9. BMC Cancer 17:1.
Crossref
Crossref
Suzannah J Chapman, Daniel McKavanagh, Matthew E Burge, Ian McPherson, Euan Walpole & Samantha A Hollingworth. (2017) Effectiveness of bevacizumab and cetuximab in metastatic colorectal cancer across selected public hospitals in Queensland. Asia-Pacific Journal of Clinical Oncology 13:5, pages e253-e261.
Crossref
Crossref
Julia Quidde, Laura Denne, Andreas Kutscheidt, Manfred Kindler, Andreas Kirsch, Melanie Kripp, Volker Petersen, Matthias Schulze, Jörg Seraphin, Dirk Tummes, Dirk Arnold & Alexander Stein. (2017) Baseline and On-Treatment Markers Determining Prognosis of First-Line Chemotherapy in Combination with Bevacizumab in Patients with Metastatic Colorectal Cancer. Oncology Research and Treatment 40:1-2, pages 21-26.
Crossref
Crossref
Nava Siegelmann-Danieli, Ariel Farkash, Itzhak Katzir, Janet Vesterman Landes, Hadas Rotem Rabinovich, Yossef Lomnicky, Boaz Carmeli & Naama Parush-Shear-Yashuv. (2016) A Novel Computational Tool for Mining Real-Life Data: Application in the Metastatic Colorectal Cancer Care Setting. PLOS ONE 11:5, pages e0154689.
Crossref
Crossref